Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.30%
#2 Victoria VR Victoria VR +9.12%
#3 Movement Movement +8.40%
#4 COTI COTI +7.33%
#5 DMT-NAT DMT-NAT +6.93%
#6 Palladium Network Palladium Network +4.63%
#7 Prom Prom +4.55%
#8 Test Test +4.07%
#9 GRVT Token GRVT Token +3.80%
#10 Cryptopia Cryptopia +3.74%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Innovation1 Biotech Inc. Innovation1 Biotech Inc.

Innovation1 Biotech Inc.

IVBT
Rang in Aktien #42121
Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily... Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily engaged in creating modified botanical Schedule 1 molecules for use within the United States. The firm's pipeline encompasses five entirely synthetic, proprietary prodrugs that are currently in preclinical development, each designed to tackle a unique set of medical conditions. Specifically, these include a psychedelic compound derived from mushrooms, aimed at treating post-traumatic stress disorder and depression; an innovative cannabinoid and tree bark-sourced psychedelic intended to combat addiction; and three additional cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and inflammation of the eye. Established in 2014 and headquartered in New York, New York, the company was previously named Gridiron BioNutrients, Inc. before adopting its current moniker, Innovation1 Biotech Inc., in March 2022.
Aktienkurs
$0.0002
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$4.49K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Innovation1 Biotech Inc. (IVBT)

Kategorie

Healthcare
P/S-Verhältnis für Innovation1 Biotech Inc. (IVBT)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Innovation1 Biotech Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Innovation1 Biotech Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR